Skip to main content
Schizophrenia Bulletin logoLink to Schizophrenia Bulletin
. 2025 Oct 30;52(5):sbaf194. doi: 10.1093/schbul/sbaf194

Protein Disulfide Isomerase A3, a Stress Response Gene, Is Associated with Cognitive Impairment in Schizophrenia and Linked to Inflammatory Activation

Xi Su 1,2,3,4,5,✉, Xiaoyun Fan 6,7, Jinming Li 8,9, Ranran Li 10,11, Jiewei Liu 12, Yongfeng Yang 13,14,15,16,17, Meng Song 18,19,20,21,22, Minglong Shao 23,24,25,26,27, Yong Han 28,29,30,31,32, Qing Liu 33,34,35, Luwen Zhang 36,37,38, Chuansheng Wang 39,40,41,42,43, Luxian Lv 44,45,46, Wenqiang Li 47,48,49,50,51,✉
PMCID: PMC13645812  PMID: 41165200

Abstract

Background and Hypothesis

Protein disulfide isomerase A3 (PDIA3), a critical regulator of endoplasmic reticulum stress, was identified as a risk gene in schizophrenia (SZ). This implies the role of PDIA3 in SZ-associated immune dysregulation.

Study Design

We integrated Psychiatric Genomics Consortium and PsychENCODE expression quantitative trait loci data, employing summary data-based Mendelian randomization analyses to investigate PDIA3-SZ associations. Clinical characterization and C-reactive protein (CRP)-based inflammatory profiling were analyzed in people with SZ categorized by PDIA3 genotypes. Plasma PDIA3 levels were quantified and correlated with clinical profiles, CRP concentrations, and white matter density. Hierarchical linear regression with mediation modeling characterized PDIA3-CRP-cognitive interactions. Finally, LOC14 (a PDIA3 inhibitor) was administered in mice to elucidate its role in SZ-related pathobiology.

Study Results

PDIA3 was identified as a robust SZ risk factor, and people with SZ carrying the risk A allele of rs7174732 in PDIA3 gene exhibit more severe cognitive impairment and a trend toward higher plasma CRP levels. Plasma PDIA3 in people with SZ was positively correlated with cognition and white matter density of the hippocampus, and negatively correlated with CRP levels. Furthermore, decreased plasma PDIA3 level in people with SZ was a significant predictor of worse working memory, and CRP acted as a mediator with an 16.2% effect. Inhibition of PDIA3 in mice was associated with increased anxiety, impaired cognition, and increased power in low-frequency signals in vivo, alongside activated inflammatory responses and regulated SZ-related biological pathways.

Conclusions

We established a PDIA3-CRP-cognitive interaction network in SZ.

Keywords: schizophrenia, PDIA3, cognition, inflammation

Introduction

Schizophrenia (SZ), a devastating psychiatric illness, affects approximately 1% of the worldwide population.1 In each patient, clinical features are highly heterogeneous and include positive symptoms, negative symptoms, and cognitive impairment.2,3 The greatest clinical challenge is the inability of the existing drug treatments to effectively improve cognitive impairment.

Endoplasmic reticulum (ER) stress is a common core pathological feature of many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.4,5 In addition, there is growing evidence relating ER stress to psychiatric disorders, such as major depression, bipolar disorder, and SZ.6,7 Animal studies have shown that ER stress modulators, such as 4-phenylbutyric acid and taurine ursodeoxycholic acid, could improve neuronal dysfunction in neuropsychiatric disorders.8,9 These molecules improved the folding capacity of the ER and stabilized protein conformation, thereby improving dendritic spine structure, saving neuronal function, and improving memory.9 In addition, many drugs for the treatment of mental disorders, such as olanzapine, valproate, and lithium, regulate ER stress.10–13

Protein disulfide isomerase (PDI) family genes are important mediators in the ER-stress induced unfolded protein response (UPR), which promotes protein folding and maintains cellular homeostasis.14 In addition to its classical role as a disulfide isomerase and chaperone, PDIAs can play a role in cell membrane signal transduction.14 Furthermore, stress-reactive PDIAs may affect the transcription levels of genes associated with cell survival and differentiation by directly or indirectly interacting with DNA targets and/or transcriptional regulators, which recognize gene regions that regulate cellular stress responses.15 Protein disulfide isomerase A3 (PDIA3) is an essential multifunctional member of the PDI family, which has been recognized as an important mediator of the cell stress response in several neurodegenerative diseases.16,17 Deregulation of PDIA3 has been implicated in a variety of pathologies, including neurodegenerative diseases.18,19

Systemic inflammation constitutes a hallmark of SZ pathophysiology.20 Emerging evidence implicates ER stress-immunity coupling as a conserved mechanism driving inflammatory cascades across neural and peripheral compartments.21 Cells suffering stress can also send alarmins which recruit and activate immune cells. In addition, ER stress can also trigger signaling pathways, such as NF-κB signaling, which are connected to the induction of inflammatory response.21 These convergent observations motivate our central hypothesis: ER stress-primed immune disturbances represent a fundamental pathobiology of SZ. A recent genome-wide association study (GWAS) of SZ identified the stress response gene PDIA3 as a susceptibility gene for this disease.22 However, the molecular mechanisms of PDIA3 involvement in SZ remain unclear. Here, we used the Psychiatric Genomics Consortium database, PsychENCODE expression quantitative trait loci (eQTL) database, summary data-based Mendelian randomization (SMR) analyses, GEO public database, clinical analysis, mediated effect analysis and animal research to systematically investigate PDIA3’s pathological role in SZ, and to identify whether PDIA3 deficiency acts as a novel immune dysfunction mechanism driving SZ pathogenesis.

Methods

SZ GWAS Dataset

The association of PDIA3 (±150 kb) with the risk of SZ was analyzed in the largest GWAS database of SZ conducted by the PGC3, which contains 71 554 SZ/schizoaffective disorder cases and 97 863 healthy controls. Detailed information can be obtained from https://pgc.unc.edu/for-researchers/download-results/.

PsychENCODE eQTL Datasets

We utilized PsychENCODE eQTL data to examine the impact of risk SNPs on mRNA expression in human dorsolateral prefrontal cortex (DLPFC) tissue. The eQTL summary data in BESD format can be downloaded at https://cnsgenomics.com/software/smr.

SMR Analyses

SMR analyses use SNPs as instrumental variable to assess the causal relationship between an exposure (gene expression) and an outcome (SZ). We respectively integrated the PsychENCODE DLPFC eQTL datasets with the SZ PGC3 GWAS to perform the SMR analyses (version 1.03). p-values derived from SMR analyses were adjusted for multiple testing using the Benjamini-Hochberg False Discovery Rate (FDR) method (P < .05). The heterogeneity in dependent instruments (HEIDI) test was conducted to distinguish true causal associations from linkage disequilibrium effects (PHEIDI < 0.05). Approximately 10 000 genes from the DLPFC eQTL datasets were analyzed. Genes meeting SMR FDR < 0.05, HEIDI P > .05, eQTLs P < 1 × 10−5 were identified as potential SZ susceptibility genes.

Genotyping and SNP Selection

Genomic DNA from 113 people with SZ was isolated using the plasma genomic DNA extraction Kit (Tiangen Biochemical Technology, DP348). Genetic information in this study was derived using the ASA-CHIA genotyping platform, a tool collaboratively developed by Gaokai Biotechnology and Illumina. Genotyping was also performed using the TaqMan probe method with TaqMan™ Genotyping Master Mix (Applied Biosystems™, 4 371 355) and the corresponding primers (Table S8), following the manufacturer’s instructions. The final genotyping results were determined through a combined analysis of the chip data and TaqMan assay results.

The rs7174732 locus in PDIA3 was selected based on the following rationale: First, 18 shared SNPs were identified through overlapping analysis of positive SNPs from GWAS (Table S1) and eQTL datasets (Table S2). Functional annotation (Table S3) revealed that 3 of these SNPs directly correspond to the PDIA3 gene, and rs7174732 exhibited the highest genetic risk among them based on genetic P-value comparison. Additionally, among the 18 SNPs, rs7174732 was the only one with available reference data in our own GWAS dataset, supporting its suitability as the target locus for subsequent analyses.

Participants and Clinical Assessment

People with SZ were recruited from the Second Affiliated Hospital of Xinxiang Medical University (Xinxiang, Henan, China). Each patient underwent scale assessment, including the Positive and Negative Syndrome Scale (PANSS) and MATRICS Consensus Cognitive Battery (MCCB), to assess symptoms and cognitive function.23

Information was obtained regarding gender, age, body mass index, smoking status, education level, duration of illness, and medications. The Ethics Committee of the Second Affiliated Hospital of Xinxiang Medical University approved this study and all participating patients provided written informed consent.

Measurement of Plasma PDIA3 Levels

PDIA3 levels in plasma were measured using the human PDIA3 96 T quantitative enzyme-linked immunosorbent assay kit (Jiangsu Jingmei Biotechnology Co., Ltd.). The specific protocol was carried out according to the instructions of the kit (Catalog No: JM-04478H1).

Image Data Acquisition and Preprocessing

MRI data were collected using a 3.0-T MR scanner (Siemens, Verio, Germany). Acquisition parameters for T1-weighted scans were as follows: repetition time = 2530 ms, echo time = 2.43 ms, inversion time = 1100 ms, flip angle = 7°, matrix size =256 × 256 × 192, and voxel size =1 × 1 × 1 mm. White matter density maps were obtained from T1 images using the computational anatomy toolbox (http://www.neuro.uni-jena.de/cat/) of the Statistical Parametric Mapping (http://www.fil.ion.ucl.ac.uk/spm/) package.

C-Reactive Protein Quantification

The C-reactive protein (CRP) levels were obtained from the electronic medical record system of the Second Affiliated Hospital of Xinxiang Medical University. CRP concentrations in the peripheral blood of people with SZ were determined using the Beckman AU5800 Latex CRP method (Beckman Coulter, Brea, CA, USA) with the latex-enhanced immunoturbidimetric high-sensitivity CRP detection kit (Zybio Inc., CHONGQING, China) at the clinical laboratory in the Second Affiliated Hospital of Xinxiang Medical University.

Animal Treatment and Behavioral Test

Experiments were conducted using adult male C57BL/6 J mice (n = 14). All animals were randomly divided into 2 groups, the normal control (NC) and intervention (LOC14) groups, which were intraperitoneally injected with 3% DMSO or 20 mg/kg LOC14 (MedChemExpress, HY-100432), respectively. After 1 week of continuous injection, a series of behavioral tests related to neurological functions were successively performed, including the open field test, the elevated plus maze test, the Y-maze, the novel-object preference test, the tail suspension test, and prepulse inhibition (PPI). The methods of behavioral tests can be found in Supplementary material. All animal experiments were approved by the Animal Ethics Committee of the Henan Provincial Psychiatric Hospital.

RNA Extraction and Quantification

Homogenized hippocampal tissues were treated with TRIzol™ reagent (Takara, T9108) following the manufacturer’s guidelines. Purified RNA was converted to cDNA using the PrimeScript RT reagent kit (novoprotein, E047-01B) under standardized conditions. Quantitative real-time PCR was conducted on the ABI Q6 System (Applied Biosystems) with the QuantiTect SYBR Green kit (Thermo Fisher, A25742) and target-specific primers (Table S8). Relative mRNA expression levels were calculated via the 2−ΔΔCT method, with GAPDH serving as the endogenous control.

Western Blotting

Brain tissues were homogenized in a buffer (Beyotime, P0013B) containing protease inhibitor mixture (Proteintech, PR20016) and PMSF (Beyotime, ST506). Following SDS-PAGE, proteins were transferred to polyvinylidene fluoride membranes (Cytiva, 10 600 023). We used TBST with 5% skimmed milk to block the membranes. The primary antibodies used were anti-PDIA3 (Boster, PB9772), anti-Iba1 (GeneTex, GTX100042), anti-NF-κb (Proteintech, 66 535-1), anti-Histone H3(Beyotime, AF0009), anti-actin (Proteintech, 66 009-1), and anti-GAPDH (Boster, BM3874) at a 1:1000 dilution. The second antibodies were HRP-conjugated antibodies (Proteintech, SA00001-2/1) at a 1:10 000 dilution. The proteins were visualized on an Amersham Imager 600 system (GE RPN2232) using an Enhanced Chemiluminescence Plus detection kit (Proteintech, PK10003). Western blot band intensity was quantified using the Image J software.

Nuclear and Cytoplasmic Proteins Extraction

The extraction of nuclear and cytoplasmic proteins from the tissue was performed using a specific kit (Beyotime, P0027). The tissue was finely shredded and then combined with reagents A and B, supplemented with 1 mM PMSF (Beyotime, ST506). The mixture was thoroughly homogenized on ice. Following a 15-min incubation period on ice, the sample was centrifuged at 1500 g for 5 min at 4°C. The resulting supernatant, which contained cytoplasmic proteins, was collected. The remaining pellet was resuspended in reagents A and B with 1 mM PMSF and vortexed for 5 s. This suspension was kept on ice for another 15 minutes before being centrifuged at 12 000-16 000 g for 5 min at 4°C. Subsequently, the pellet was resuspended in the nuclear protein extraction buffer containing 1 mM PMSF and shaken gently at 4°C for 30 min. Afterward, the sample was centrifuged again at 12 000-16 000 g for 10 min at 4°C, and the supernatant, which contained nuclear proteins, was collected. Histone H3 was used as the control protein for the nuclear fraction, while GAPDH served as the control for the cytoplasmic fraction.

Immunofluorescent Staining

The heart was perfused with saline until all the blood was thoroughly removed, after which they were perfused with 4% paraformaldehyde. The brains were then carefully extracted and re-fixed in 4% paraformaldehyde overnight. Subsequently, they were subjected to a sucrose gradient treatment involving concentrations of 15%, 20%, and 30%. Brain tissues were embedded in optimal cutting temperature compound, and coronal sections of 10 μm thickness were obtained using a cryostat (Leica, CM1950). Antigen retrieval was performed using sodium citrate solution in a microwave oven, followed by 3 washes with PBS. Sections were incubated in 0.5% Triton X-100 for 10 min and then washed three times with PBS, each for 10 min. Slides were blocked with 1% bovine serum albumin at 37°C for 1 h and subsequently incubated with Iba1 primary antibodies (GeneTex, GTX100042) at a 1:100 dilution overnight. After washing with PBS, sections were incubated with secondary antibodies (Beyotime, A051), diluted at 1:500, for 1 h. Finally, nuclear staining was performed using Hoechst 33258 (Beyotime, C1018) for 10 min, followed by a PBS wash. The prepared slides were examined under a microscope (Nikon Ci-L), and images were captured.

In Vivo Multichannel Electrophysiology

Mice were anesthetized with isoflurane and their heads were fixed using a brain stereotaxic apparatus (RWD Life Science, DOM-1001). The skin on their heads was incised to expose the anterior and posterior fontanelles, which were disinfected with iodine. The heads were positioned with the anterior and posterior sides flat to ensure the cranial surface was level. The anterior fontanelle is the zero point and locates the right hippocampus (X = 2.5 mm, Y = 3.5 mm, Z = 2 mm). A hole was drilled above the right hippocampus and the electrode was slowly implanted into the brain at a rate of 1 mm/min and at a depth of 2 mm. The intervention was given for 3 consecutive days after surgery, and the local field potential (LFP) was subsequently collected from the hippocampal region of the mice. LFP data were amplified (gain: 5000), filtered (HP250 Hz), sampled at 1 kHz, and recorded for 5 min. Data were sampled using a Cereplex recording system (Blackrock Microsystems).

Data Analysis

Unpaired two-tailed Student’s t-tests were used to compare differences between two groups. Partial correlation analysis (controlling for covariates including age, years of education, duration of illness, and chlorpromazine equivalents) was performed to explore the relationship between PDIA3 levels and the PANSS and MCCB scores. Univariate linear regression was used to identify factors potentially associated with the MCCB scores, where MCCB scores served as the dependent variable and each candidate factor (including age, years of education, duration of illness, sex, and chlorpromazine equivalents) as the independent variable. Variables with a P-value <.05 in univariate analyses were further entered into multiple linear regression models to examine the specific influence of PDIA3 and CRP levels on MCCB scores. Specifically, Model 1 included plasma PDIA3 levels as the independent variable, adjusted for the mentioned covariates (P-value <.05) to predict Brief Assessment of Cognition in Schizophrenia - Symbol Coding (BACS SC) scores. Model 2 added CRP as an additional independent variable to Model 1, with adjustments for the same covariates. The mediating effect of CRP levels was assessed using Model 4 proposed by Hayes.24 Statistical analyses were conducted using SPSS 26.0 and the “PROCESS” macro (version 3.5.1) in SPSS. FDR correction was used in the analysis of multiple comparisons. Statistical significance is indicated by * for P < .05 and ** for P < .01. Data are expressed as mean ± SEM.

Results

PDIA3 Was Associated with SZ

The association of PDIA3 with SZ was analyzed in the PGC3 SZ GWAS database and PsychENCODE eQTL database (Figure 1A and B). 32 SNPs in PDIA3 were associated with SZ (Figure 1A), with relevant information presented in Table S1. 53 SNPs (PFDR < .05) were significantly associated with mRNA levels of PDIA3 in the PsychENCODE database (Figure 1B), and 18 of them were genetic risk factors. The relevant information was presented in Table S2. SMR analyses integrating SZ PGC3 GWAS and PsychENCODE eQTL datasets identified that PDIA3 was significantly associated with increased genetic risk of SZ (Figure 1C).

Figure 1.

Figure 1

The association of PDIA3 and SZ. (A) Associations of SNPs in PDIA3 with risk of SZ in PGC3 GWAS, rs7174732 and its linkage disequilibrium-linked SNPs were marked. (B) Associations of SNPs in PDIA3 with PDIA3 mRNA expression in PsychENCODE dataset. (C) SMR analyses through integrating SZ PGC3 GWAS with brain PsychENCODE eQTL dataset

PDIA3 Was Correlated with BACS SC Score and Inflammation Levels in People with SZ

We selected rs7174732 in PDIA3 gene (PGWAS = 2.928E-10, PeQTL = .0006) for analysis, and found that people with SZ carrying the risk A allele of rs7174732 in PDIA3 gene took more time to complete the Trail Making Test and write fewer symbols in the 90-s BACS SC test (Figure 2A and B and Table S4), indicating more severe cognitive impairment. In addition, peripheral plasma CRP levels in patients carrying risk mutation showed a trend of elevation, although no statistical difference was observed (Figure 2C).

Figure 2.

Figure 2

The correlation between PDIA3 and cognition, inflammation, and white matter density in people with SZ. (A-C) People with SZ carrying the risk a allele of rs7174732 in PDIA3 gene take more time to complete trail making test (A), write fewer symbols in the BACS SC test (B), and exhibited a trend toward higher plasma CRP levels in peripheral blood (C). (D-F) Correlation analysis among plasma PDIA3 levels, inflammation, and cognitive function in people with SZ. (G-I) the correlation between the PDIA3 level and white matter density in the hippocampus (Braninnetome atlas label 215, 217)

Next, the mRNA expression levels of PDIA3 in the brain region of people with SZ, including the hippocampus, prefrontal cortex, striatum, cerebellum, endothelial cells, and neurons, were analyzed in the GEO profile database. While PDIA3 mRNA levels showed a downward trend in the prefrontal cortex, striatum, endothelial cells, and neurons, these differences did not reach statistical significance (Figure S1). In contrast, significant reductions in PDIA3 mRNA were observed in the hippocampus and cerebellum of people with SZ compared with healthy controls (Figure S1A and F). The plasma levels of PDIA3 in people with SZ were examined and their correlation analyses between these levels and the PANSS, MCCB scores, and CRP were performed (Figure 2D-F, Tables S5 and S6). Specifically, plasma PDIA3 was significantly positively correlated with the BACS SC scores (r = 0.282, P = .003) and significantly negatively correlated with the CRP levels (r = −0.212, P = .029). In addition, the plasma CRP levels were significantly negatively correlated with the BACS SC scores (r = −0.269, P = .005) (Figure 2F and Table S6).

Plasma PDIA3 Levels in SZ Correlated with White Matter Density

Based on the significant reduction of PDIA3 in hippocampal regions of people with SZ, we extracted the white matter density of the hippocampus based on the 246 partitions of the Brainnetome atlas from magnetic resonance images, and found that white matter density in the hippocampus (Brainnetome atlas label 215 and 217) was positively correlated with plasma PDIA3 (r = 0.2125, P = .0443; r = 0.2287, P = .0302) (Figure 2G-I).

CRP Mediated the PDIA3-BACS SC Scores Association in People with SZ

Univariate linear regression identified that age and duration of illness were significantly correlated with BACS SC scores (Figure 3A), and thus these factors were included as covariates in the subsequent multiple linear regression analyses. The results of Model 1 confirmed that plasma PDIA3 was a significant predictor of working memory (β = 0.213, 95% CI, 0.032-0.297, P = .016). The Model 1 was significant (R2 = 0.090, F = 4.443, P = .005), accounting for 9.0% of the variance. In the Model 2, both plasma PDIA3 (β = 0.238, 95% CI, 0.035-0.327, P = .016) and CRP (β = −0.206, 95% CI, −2.168 to −0.108, P = .031) were significant predictors of BACS SC scores (Figure 3A). The Model 2 was significant and accounted for 18.2% of the variance in the BACS SC scores (R2 = 0.182, F = 5.836, P < .001) (Figure 3A).

Figure 3.

Figure 3

Mediation analysis of CRP between PDIA3 and cognition. (A) Regression analysis to determine the association between PDIA3, CRP, and BACS SC AGET scores. Model 1 linear regression of PDIA3 on BACS SC scores after adjusting for age and duration of illness. Model 2 adjusted for the same variables as model 1, as well as for CRP. aP indicates that the correlation is significant at a confidence (two-test) of .05; bP indicates that the correlation is significant at a confidence (two-test) of .01; #P indicates that the correlation is significant at a confidence (two-test) of .001. (B) Mediation analysis of CRP between PDIA3 and cognition. All path coefficients were standardized. a is the effect of the independent variable on mediators; b is the effect of mediators on dependent variables after controlling the influence of independent variables; c′ and c is the direct effect and total effect of independent variables on dependent variables. *P < .05. **P < .01

Next, we evaluated the mediating effect of CRP levels on the relationship between PDIA3 levels and BACS SC scores using PROCESS v3.5. A model assessing CRP levels as a mediator of the relationship between PDIA3 levels and BACS SC scores showed a significant indirect effect (β = 0.046, 95% CI, 0.001-0.092, SE = 0.023, Figure 3B) and a significant direct effect (β = 0.238, 95% CI, 0.035-0.327, SE = 0.074, Figure 3B), indicating partial mediation. Furthermore, the mediating effect accounted for 16.2% of the total effect (0.046/0.284, Figure 3B).

PDIA3 Inhibition Is Associated with Abnormalities in Behavior and Electrophysiological Signals, with Concurrent Inflammatory Activation

Our clinical results indicated that decreased PDIA3 levels were associated with poor cognition. We validated these findings in mice through the administration of LOC14, a PDIA inhibitor. Intraperitoneal injection of LOC14 at a 20 mg/kg dose significantly decreased PDIA3 protein expression in the hippocampus of mice (Figure 4A). Open field test and elevated plus maze were used to test the anxiety levels of the mice. In the open field test, LOC14 treatment had no significant effect on the exploration in the central area (Figure 4B and Figure S3A). In the elevated plus maze test, compared with the NC group, LOC14-treated mice exhibited a significant reduction in the number of entries into the open arms (Figure 4C). Although movement distance and exploration time within the open arms demonstrated a decreasing trend in the LOC14 group, these differences did not reach statistical significance (Figure 4C and Figure S3B). These observations indicated no significant increase in anxiety levels in mice treated with LOC14. Y-maze and novel-object preference were used to test the cognition of the mice. Mice in the LOC14-treated group showed less exploration of the novel arm of the Y maze, but the difference was not statistically significant (Figure 4D and Figure S3C). In the novel-object preference test, mice from LOC14 treatment condition showed a decreased preference for the new object, as indicated by the percentage of exploration time calculated as T2/(T1 + T2) (Figure 4E), suggesting an impaired cognition in the mice from the LOC14 group. Tail suspension test was used to evaluate depression-like behavior, with no difference detected in the resting time between the LOC14-treated and the NC groups (Figure S3D). The PPI test was used to evaluate the sensory gating function of the mice, although the LOC14 treatment had no significant effect on PPI, the treatment significantly increased the startle response at 120 dB during PPI test (Figure 4F). In addition, the electrophysiological signals in the hippocampus of the mice were in vivo analyzed. LOC14-treated mice showed increased energy value, especially at Delta, Theta, and Alpha oscillations (Figure 4G-I). Taken together, the inhibition of PDIA3 in mice resulted in SZ-like abnormalities in behavior (including increased anxiety, impaired memory, and enhanced startle response) and in the electrophysiological signals.

Figure 4.

Figure 4

PDIA3 inhibition results in abnormalities in the behavior and LFP in mice. (A) The intraperitoneal injection of LOC14, a PDIA3 inhibitor, significantly reduces PDIA3 expression in the hippocampus (n = 4 per group). (B-F) Behavioral assay (n = 7 per group). (B) The proportion of the distance moved in the central region and the number of entries into the central region of the open field test. (C) The proportion of the distance moved in the open arm, the number of entries into the open arm and the time spent in the open arm. (D) The proportion of the distance moved in the novel arm, the number of entries into the novel arm and the time spent in the novel arm. (E) The preference for the novel object was calculated as the percentage of time spent exploring it. (F) PPI, the startle response at 120 dB and the percentage of inhibition of startle stimulus responses (120 dB) to prepulse stimulus (72 dB, 77 dB, 82 dB). (G-I) In vivo electrophysiological detection. (G) LFP analysis of 0-100 Hz. (H) Power spectra for continuous in the low frequency band (0-100 Hz). (I) LFP analysis of Delta, Theta, Alpha, Beta, and Gamma bands

To further investigate the potential mechanisms underlying these phenotypic abnormalities, RNA sequencing and subsequent validation were carried out. Based on the results that PDIA3 had the greatest change in the hippocampus of people with SZ (Figure S1) and PDIA3 is associated with hippocampal white matter (Figure 2G-I), we selected the hippocampus for transcriptome analysis. We identified 498 altered genes (173 up-regulated and 325 down-regulated genes) that were differentially expressed between the NC and the LOC14 groups. All differentially expressed genes are shown in Figure 5A. Through functional enrichment analysis of differentially expressed genes, we found that most of the up-regulated genes in the LOC-treated group were correlation with immunity as indicated by red fonts (Figure 5B and C), which coincided with our clinical findings. Gene Set Enrichment Analysis (GSEA) of the up-regulated expressed genes revealed the enhanced microglial-related functions in the LOC14 group (Figure 5D). Based on this, we analyzed microglia in the hippocampus. The results of immunoblot and immunofluorescent staining indicated that the hippocampus from mice in the LOC14 group showed elevated Iba1 expression (Figure 5E and F). Furthermore, based on the GSEA of up-regulated expressed genes in the NF-κB pathway (Figure 5G) and the centrality of NF-κB in the immune response, we analyzed the NF-κB content in the nucleus as well as the transcript levels of cytokines activated by this pathway. The results showed that LOC14 treatment increased the level of NF-κB in the nucleus (Figure 5H) and increased the mRNA levels of IL-6, TNF-α, IL-1β, and IFN-γ (Figure 5I), suggesting that LOC14 treatment promoted NF-κB-mediated immune activation.

Figure 5.

Figure 5

PDIA3 inhibition results in activation of inflammatory response in mice. (A) Expression heatmap showing differentially expressed genes in the hippocampus of control and LOC14-treated mice. (B and C) GO analysis and KEGG analysis of upregulated expressed genes identified by RNA-Seq. Red font showed biological functions or pathways related to immune. (D) GSEA of microglia pathogen phagocytosis pathway. (E and F) Representative images of immunoblotting and immunofluorescence of Iba1 in the hippocampus of control and LOC14-treated mice, and statistical analysis. Scale bar, 20 μm. (G) GSEA of NF-κB signaling pathway. (H) NF-κB detection in the whole cells and nuclei in the hippocampus. (I) The mRNA levels of proinflammatory cytokine in the hippocampus. Data are expressed as mean ± SEM. Student’s t-test was used to assess statistical significance. *P < .05. **P < .01

PDIA3 Regulates SZ-Related Biological Pathways

The downregulated 325 genes accounted for 65% of the variance, and we performed functional enrichment analysis of the down-regulated expressed genes. The results of the GO enrichment analysis showed that the most significant biological process was neurotransmitter transport (Figure S4A). The results of the GSEA also showed that the downregulated genes were involved in biological pathways related to neurotransmitter systems, synapse-associated cellular components, and GABAergic and glutamatergic molecular function (Figure S4C and D). These results are in agreement with the KEGG enrichment analysis (Figure S4B). Among the significantly downregulated genes (sorted according to their log2 fold change), nine differentially downregulated genes were associated with brain function (including Gsta2, Prokr1, Slc6a12, Slc22a2, Foxc2, Agmat, Omd, CTXN3, and Tcap).25–31 In agreement with the RNA-Seq data, qPCR results showed that in comparison with the NC group, Slc6a12, Slc22a2, Agmat, CTXN3, and Tcap were significantly down-regulated in the hippocampal tissues of mice in the LOC14 group (Figure S4E).

Intriguingly, the abnormal neurotransmitter systems, anomalous signaling pathways, and molecules found in LOC14-treated mice have all been highlighted in studies on SZ.32 Therefore, PDIA3 may participate in SZ pathogenesis via the modulation of these pathways or molecules.

Discussion

In this study, we found that PDIA3, a stress response gene, is a risk factor for SZ, and people with SZ who carry risk mutations present more severe cognitive impairment and a trend toward higher CRP levels. A defective expression of PDIA3 was found in the SZ brain tissue. In people with SZ, the PDIA3 plasma levels were positively correlated with both the BASC CS scores in the MCCB and white matter density in hippocampus, with CRP exerting a mediating effect. In addition, inhibition of PDIA3 in mice resulted in increased anxiety, impaired cognition, increased field potential power, and immune activation in the hippocampus.

Impaired PDIA3 function is involved in many neurological disorders.33 PDIA3 is a molecular chaperone primarily found in the ER and involved in the correct folding of proteins, and associated with ER stress and immune inflammation.34 When the ER becomes overwhelmed and unable to properly fold proteins, PDIA3 modulates this process to maintain proper cellular function and homeostasis.35 Neurodegenerative diseases, such as Parkinson’s disease and amyotrophic lateral sclerosis, are characterized by ER stress.36–40 Overexpression of PDIA3 inhibited ER stress,41,42 and the knockdown of PDIA3 expression enhanced ER stress,43 therefore, PDIA3 exerts a neuroprotective function. A GWAS study reported that PDIA3 was a SZ risk gene.44 SZ is a disease involving oxidative stress and inflammatory responses. PDIA3 may act as a response molecule by modifying stress response. Interestingly, our study did not detect any changes in the peripheral plasma levels of PDIA3 in people with SZ (Figure S2), compared with healthy controls. This observation is consistent with previous studies that found no abnormalities in PDIA3 mRNA levels in postmortem brain tissues of people with SZ.45 One possible explanation could be the different disease states. Furthermore, PDIA3 expression may exhibit tissue or brain regional specificity. This interpretation is supported by our data (Figure S1), which showed that not all observed PDIA3 alterations across different brain regions or cell types reached statistical significance. A previous study in traumatic brain injury patients reported that the levels of PDIA3 were significantly increased in the late traumatic phase, rather than in the early and acute phases of traumatic brain injury.46 However, considering the basic biological role of PDIA3, we hypothesize that, in people with SZ often associated with ER stress, PDIA3 fails to respond in a timely manner, which could be the pathological basis of this disease. This hypothesis needs further confirmation.

Cognitive impairment is a core feature of SZ. PDIA3 acts as a protective factor for cognitive function and represents a potential target for cognition improvement. Diosgenin, an exogenous PDIA3 activator, induces neuronal axon growth and significantly improves object recognition memory performance in Alzheimer’s disease mouse models.47 Diosgenin treatment in normal mice enhanced object recognition memory and spike firing in hippocampal CA1.48 Based on results showing that PDIA3 levels were correlated with the BACS SC scores in the MCCB and that inhibition of PDIA3 activity could lead to cognitive deficits in mice, our results indicated that PDIA3 is a protective factor for cognition and PDIA3 activation may be a potential strategy for cognitive improvement in people with SZ.49

PDIA3 is an immune-related gene, which may be involved in immune disorders related to SZ. There are many observations of immune dysfunction in SZ, including alterations in peripheral and central immune markers, especially cytokine abnormalities, as well as immune cell activation. PDIA3, a key component of the major histocompatibility complex class I peptide loading complex, is associated with the immune response, including activation of immune cells and the inflammatory signaling pathway.50 A previous study indicated that PDIA3 plays an essential role in human microglia activation by Aβ and may be a therapeutic target for Alzheimer’s disease treatment.51 A study on glioblastoma also supports its role in microglia activation.17 Another study found that PDIA3 supplementation could ameliorate the ischemia-induced activation of glia cells, both microglia and astrocytes.52 Furthermore, membrane-located PDIA3 mediates multiple rapid signal transduction pathways, including the STAT3 and the NF-κB pathways, regulating the expression of proinflammatory cytokines. In addition, PDIA3 could regulate leukemia cell differentiation by complexing with NF-κB.53 This study also confirmed the possible relationship between PDIA3 deficiency and immune response in both people with SZ and animal experiments. Defects in PDIA3 may be a pathological basis for immune disorders in SZ, at least in populations with a risk of genetic defects in PDIA3.

Beyond its established role in immune responses, the present study further indicates that PDIA3 may exert its biological effects through additional pathways, encompassing a range of molecules and signaling cascades associated with SZ. Our experimental results revealed that LOC14 treatment significantly downregulated the expression of SLC6A12, SLC22A2, and CTNX3. Notably, prior research has demonstrated that mutations in CTNX3 and SLC6A12 are linked to the pathogenesis of SZ,30 while SLC22A2 has been implicated in the regulation of psychiatric symptoms.31 Furthermore, our findings uncovered that LOC14 intervention induced disturbances in the neurotransmitter system, a phenomenon that has long been recognized as closely associated with SZ. However, the specific correlations between PDIA3, these molecular changes, and neurotransmitter system dysfunction remain to be fully elucidated.

The occurrence and development of SZ are caused by the interaction between environmental and genetic factors. We propose a biological model in which defective ER stress responses explain the possible mechanisms by which environmental factors contribute to the disease onset in susceptible populations, or to the degradation of the disease (Figure S5). Briefly, individuals susceptible to SZ (such as individuals with PDIA3 genetic deficiency and others) or with chronic SZ, encounter adverse environmental factors (called stressors), which activate many ER stress signaling pathways (including inflammation, redox imbalance, and abnormal calcium homeostasis), leading to the aggregation of misfolded proteins and ER stress. In healthy individuals, the adaptive UPR is timely activated to recover environmental homeostasis, by regulating gene transcription, such as promoting the expression of molecular chaperones (including PDIA3) to enhance the protein folding ability. Moreover, the expression of autophagy-related genes is activated, to promote the clearance of misfolded proteins. However, the adaptive UPR in people with SZ is flawed, due to genetic defects (such as PDIA3 gene with risk mutations) or other mechanisms (such as autophagy defect, reported by our previous study54), leading to persistent UPR. Persistent UPR activates gene transcription (involving inflammation and reactive oxygen species), causing persistent homeostasis imbalance (even apoptosis), leading to neuronal dysfunction, and ultimately resulting in SZ onset in high-risk patients or in the degradation of patients. This is only a speculative model, and more research is needed to confirm this hypothesis.

This article has several limitations. First, the CRP data were retrieved from the medical records system, which means we cannot ensure uniform disease courses across patients, potentially affecting data analysis. Second, LOC14 may cross-react with other PDIA family members due to their structural and functional similarities; addressing this issue will require the specific regulation of PDIA3 gene expression in the future.

In conclusion, our results indicated that PDIA3 defects could be involved in the pathogenesis of impaired cognition in SZ, in which inflammation plays a mediating role. Therefore, the activation of PDIA3 might serve as a target for cognitive improvement in SZ.

Supplementary Material

Supplementary_Materials_sbaf194

Acknowledgments

The sample resources were applied from the Biobank of Henan Mental Hospital. We thank the research team of the Biobank of Henan Mental Hospital for their efforts.

Contributor Information

Xi Su, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Xiaoyun Fan, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China.

Jinming Li, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China.

Ranran Li, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China.

Jiewei Liu, Department of Psychiatry, Wuhan Mental Health Center, Wuhan 430071, China.

Yongfeng Yang, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Meng Song, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Minglong Shao, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Yong Han, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Qing Liu, Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Luwen Zhang, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China.

Chuansheng Wang, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Luxian Lv, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China.

Wenqiang Li, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, China; Brain Institute, Henan Academy of Innovations in Medical Science, Zhengzhou 451163, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, China; International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang 453002, China; Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang 453002, China.

Author Contributions

X.S., L.X.L., and W.Q.L. designed the study and interpreted the results. X.Y.F., J.M.L., R.R.L., and J.W.L. performed the data analysis and primary experiments. M.L.S., Y.F.Y., M.S., Y.H., C.S.W., and W.Q.L. contributed to the design and helped with the experiments. X.S. and X.Y.F. drafted the manuscript. All authors reviewed the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (U22A20304 to L.X.L. and 82171498 to W.Q.L.); Henan Province science and technology research and development plan joint fund (industry) major project (235101610004 to C.S.W.); and Natural Science Foundation of Henan Provincial (252300421397 to X.S.).

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

  • 1. Franke  B, Stein  J, Ripke  S, et al.  Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nat Neurosci. 2016;19:420–431. 10.1038/nn.4228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Stroup  T, Olfson  M, Huang  C, et al.  Age-specific prevalence and incidence of dementia diagnoses among older US adults with schizophrenia. JAMA psychiatry. 2021;78:632–641. 10.1001/jamapsychiatry.2021.0042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Chamera  K, Kotarska  K, Szuster-Głuszczak  M, et al.  The prenatal challenge with lipopolysaccharide and polyinosinic:polycytidylic acid disrupts CX3CL1-CX3CR1 and CD200-CD200R signalling in the brains of male rat offspring: a link to schizophrenia-like behaviours. J Neuroinflammation. 2020;17:247. 10.1186/s12974-020-01923-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Ye  B, Wang  Q, Hu  H, et al.  Restoring autophagic flux attenuates cochlear spiral ganglion neuron degeneration by promoting TFEB nuclear translocation via inhibiting MTOR. Autophagy. 2019;15:998–1016. 10.1080/15548627.2019.1569926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Xiang  C, Wang  Y, Zhang  H, Han  F. The role of endoplasmic reticulum stress in neurodegenerative disease. Apoptosis. 2017;22:1–26. 10.1007/s10495-016-1296-4 [DOI] [PubMed] [Google Scholar]
  • 6. Li  S, Zhu  Y, Wei  C, et al.  Identification of molecular correlations between DHRS4 and progressive neurodegeneration in amyotrophic lateral sclerosis by gene co-expression network analysis. Front Immunol. 2022;13:874978. 10.3389/fimmu.2022.1072573 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Yang  L, Chen  Z, Li  J, Ding  P, Wang  Y. Effects of escitalopram on endoplasmic reticulum stress and oxidative stress induced by tunicamycin. Front Neurosci. 2021;15:737509. 10.3389/fnins.2021.737509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Seo  S, Min  K, Woo  S, Kwon  T. Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-mediated apoptosis through the induction of endoplasmic reticulum stress. Exp Mol Med. 2018;50:1–11. 10.1038/s12276-018-0138-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Liu  P, Wang  X, Sun  Y, et al.  SARS-CoV-2 ORF8 reshapes the ER through forming mixed disulfides with ER oxidoreductases. Redox Biol. 2022;54:102388. 10.1016/j.redox.2022.102388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. He  M, Huang  X, Gao  G, et al.  Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate. Psychoneuroendocrinology. 2019;104:286–299. 10.1016/j.psyneuen.2019.03.017 [DOI] [PubMed] [Google Scholar]
  • 11. Zhou  R, He  M, Fan  J, et al.  The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: a narrative review. Front Neurosci. 2022;16:947295. 10.3389/fnins.2022.947295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Fu  J, Peng  L, Wang  W, et al.  Sodium valproate reduces neuronal apoptosis in acute pentylenetetrzole-induced seizures via inhibiting ER stress. Neurochem Res. 2019;44:2517–2526. 10.1007/s11064-019-02870-w [DOI] [PubMed] [Google Scholar]
  • 13. Kim  E, Meng  H, Jun  A. Lithium treatment increases endothelial cell survival and autophagy in a mouse model of Fuchs endothelial corneal dystrophy. Br J Ophthalmol. 2013;97:1068–1073. 10.1136/bjophthalmol-2012-302881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Wu  Y, Huang  X, Zheng  Z, Yang  X, Ba  Y, Lian  J. Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG-A561V protein. Int J Mol Med. 2021;48:159. 10.3892/ijmm.2021.4992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Fabarius  A, Samra  V, Drews  O, et al.  Evidence for recombinant GRP78, CALR, PDIA3 and GPI as mediators of genetic instability in human CD34+ cells. Cancers. 2022;14:2883. 10.3390/cancers14122883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Zhang  J, Wang  K, Hainisayimu  T, Li  H. Pan-cancer analysis of PDIA3: identifying it as a potential biomarker for tumor prognosis and immunotherapy. Oxidative Med Cell Longev. 2022;2022:9614819. 10.1155/2022/9614819 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chiavari  M, Ciotti  G, Canonico  F, et al.  PDIA3 expression in glioblastoma modulates macrophage/microglia pro-tumor activation. Int J Mol Sci. 2020;21. 10.3390/ijms21218214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Chichiarelli  S, Altieri  F, Paglia  G, Rubini  E, Minacori  M, Eufemi  M. ERp57/PDIA3: new insight. Cell Mol Biol Lett. 2022;27:12. 10.1186/s11658-022-00315-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Turano  C, Gaucci  E, Grillo  C, Chichiarelli  S. ERp57/GRP58: a protein with multiple functions. Cell Mol Biol Lett. 2011;16:539–563. 10.2478/s11658-011-0022-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Khandaker  GM, Cousins  L, Deakin  J, Lennox  BR, Yolken  R, Jones  PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry Mar. 2015;2:258–270. 10.1016/S2215-0366(14)00122-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Salminen  A, Kauppinen  A, Suuronen  T, Kaarniranta  K, Ojala  J. ER stress in Alzheimer’s disease: a novel neuronal trigger for inflammation and Alzheimer’s pathology. J Neuroinflammation. 2009;6:41. 10.1186/1742-2094-6-41 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427. 10.1038/nature13595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Green  M, Nuechterlein  K, Gold  J, et al.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301–307. 10.1016/j.biopsych.2004.06.023 [DOI] [PubMed] [Google Scholar]
  • 24. Hayes  AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. The Guilford Press; 2013.
  • 25. Yan  S, Xu  C, Yang  M, et al.  The expression of agmatinase manipulates the affective state of rats subjected to chronic restraint stress. Neuropharmacology. 2023;229:109476. 10.1016/j.neuropharm.2023.109476 [DOI] [PubMed] [Google Scholar]
  • 26. Hogg  D, Husić  M, Wosnick  D, Dodsworth  T, D'Aquila  A, Lovejoy  D. Activity of the carboxy-terminal peptide region of the teneurins and its role in neuronal function and behavior in mammals. Front Neurosci. 2019;13:581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Smith  M, King  J, Dent  L, et al.  Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease. Life Sci. 2014;110:1–7. 10.1016/j.lfs.2014.05.014 [DOI] [PubMed] [Google Scholar]
  • 28. Choi  Y, Shin  M, Youn  G, et al.  Protective effects of PEP-1-GSTA2 protein in hippocampal neuronal cell damage induced by oxidative stress. Int J Mol Sci. 2023;24:2767. 10.3390/ijms24032767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Maftei  D, Ratano  P, Fusco  I, et al.  The prokineticin receptor antagonist PC1 rescues memory impairment induced by β amyloid administration through the modulation of prokineticin system. Neuropharmacology. 2019;158:107739. 10.1016/j.neuropharm.2019.107739 [DOI] [PubMed] [Google Scholar]
  • 30. Panichareon  B, Nakayama  K, Iwamoto  S, Thurakitwannakarn  W, Sukhumsirichart  W. Association of CTXN3-SLC12A2 polymorphisms and schizophrenia in a Thai population. Behav Brain Funct. 2012;8:27. 10.1186/1744-9081-8-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Borghetti  A, Calcagno  A, Lombardi  F, et al.  SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74:1035–1043. 10.1093/jac/dky508 [DOI] [PubMed] [Google Scholar]
  • 32. Wang  J, Li  X, Li  H, et al.  Integrative analyses followed by functional characterization reveal TMEM180 as a schizophrenia risk gene. Schizophr Bull. 2021;47:1364–1374. 10.1093/schbul/sbab032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ghemrawi  R, Khair  M. Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int J Mol Sci. 2020;21:6127. 10.3390/ijms21176127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Shen  J, Zhan  Y, He  Q, et al.  Remifentanil promotes PDIA3 expression by activating p38MAPK to inhibit intestinal ischemia/reperfusion-induced oxidative and endoplasmic reticulum stress. Front Cell Dev Biol. 2022;10:818513. 10.3389/fcell.2022.818513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ansari  S, Sharma  A, Soni  H, et al.  Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells. Cell Death Dis. 2018;9:296. 10.1038/s41419-018-0342-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Tokuda  E, Watanabe  S, Okawa  E, Ono  S-i. Regulation of intracellular copper by induction of endogenous metallothioneins improves the disease course in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:461–476. 10.1007/s13311-015-0346-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Linda  K, Lewerissa  EI, Verboven  AHA, et al.  Imbalanced autophagy causes synaptic deficits in a human model for neurodevelopmental disorders. Autophagy. 2022;18:423–442. 10.1080/15548627.2021.1936777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Fouillet  A, Levet  C, Virgone  A, et al.  ER stress inhibits neuronal death by promoting autophagy. Autophagy. 2012;8:915–926. 10.4161/auto.19716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Wang  B, Su  C-J, Liu  T-T, et al.  The neuroprotection of low-dose morphine in cellular and animal models of Parkinson’s disease through ameliorating endoplasmic reticulum (ER) stress and activating autophagy. Front Mol Neurosci. 2018;11:120–120. 10.3389/fnmol.2018.00120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Kang  SH, Li  Y, Fukaya  M, et al.  Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16:571–579. 10.1038/nn.3357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Zhang  J, Wang  K, Hainisayimu  T, Li  H. Pan-cancer analysis of PDIA3: identifying it as a potential biomarker for tumor prognosis and immunotherapy. Oxidative Med Cell Longev. 2022;2022:9614819–9614819. 10.1155/2022/9614819 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Rozas  P, Pinto  C, Martínez Traub  F, et al.  Protein disulfide isomerase ERp57 protects early muscle denervation in experimental ALS. Act Neuropathol Commun. 2021;9:21–21. 10.1186/s40478-020-01116-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Parakh  S, Jagaraj  C, Vidal  M, et al.  ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis. Hum Mol Genet. 2018;27:1311–1331. 10.1093/hmg/ddy041 [DOI] [PubMed] [Google Scholar]
  • 44. Schizophrenia working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427. 10.1038/nature13595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Tsai  SY, Catts  VS, Fullerton  JM, Corley  SM, Fillman  SG, Weickert  CS. Nuclear receptors and neuroinflammation in schizophrenia. Mol Neuropsychiatry. 2018;3:181–191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Wang  W, Sun  L, Sun  C. PDIA3-regulted inflammation and oxidative stress contribute to the traumatic brain injury (TBI) in mice. Biochem Biophys Res Commun. 2019;518:657–663. 10.1016/j.bbrc.2019.08.100 [DOI] [PubMed] [Google Scholar]
  • 47. Tohda  C, Urano  T, Umezaki  M, Nemere  I, Kuboyama  T. Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer’s disease pathologies in 5XFAD mice. Sci Rep. 2012;2:535. 10.1038/srep00535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Tohda  C, Lee  Y-A, Goto  Y, Nemere  I. Diosgenin-induced cognitive enhancement in normal mice is mediated by 1,25D₃-MARRS. Sci Rep. 2013;3:3395–3395. 10.1038/srep03395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Bürkner  P-C, Williams  DR, Simmons  TC, Woolley  JD. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull. 2017;43:1291–1303. 10.1093/schbul/sbx053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Burassakarn  A, Phusingha  P, Yugawa  T, et al.  Human papillomavirus 16 E6 suppresses transporter associated with antigen-processing complex in human tongue keratinocyte cells by activating lymphotoxin pathway. Cancers (Basel). 2022;14. 10.3390/cancers14081944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Yoo  Y, Byun  K, Kang  T, et al.  Amyloid-beta-activated human microglial cells through ER-resident proteins. J Proteome Res. 2015;14:214–223. 10.1021/pr500926r [DOI] [PubMed] [Google Scholar]
  • 52. Yoo  D, Cho  S, Jung  H, et al.  Tat-protein disulfide-isomerase A3: a possible candidate for preventing ischemic damage in the spinal cord. Cell Death Dis. 2017;8:e3075. 10.1038/cddis.2017.473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Song  D, Liu  H, Wu  J, Gao  X, Hao  J, Fan  D. Insights into the role of ERp57 in cancer. J Cancer. 2021;12:2456–2464. 10.7150/jca.48707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Su  X, Wang  G, Liu  S, et al.  Autophagy defects at weaning impair complement-dependent synaptic pruning and induce behavior deficits. J Neuroinflammation. 2024;21:239. 10.1186/s12974-024-03235-z [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary_Materials_sbaf194

Articles from Schizophrenia Bulletin are provided here courtesy of Oxford University Press

RESOURCES